Viking Therapeutics Inc (VKTX)

NASDAQ
Currency in USD
23.940
+0.340(+1.44%)
Closed·
After Hours
24.000+0.070(+0.293%)
·
VKTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 3 days
Fair Value
Day's Range
21.23024.120
52 wk Range
18.92081.860
Key Statistics
Edit
Prev. Close
23.6
Open
22.04
Day's Range
21.23-24.12
52 wk Range
18.92-81.86
Volume
5.04M
Average Volume (3m)
4.7M
1-Year Change
-62.25%
Book Value / Share
7.9
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VKTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
95.444
Upside
+298.68%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings downwards for the upcoming period
Show more

Viking Therapeutics Inc Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Compare VKTX to Peers and Sector

Metrics to compare
VKTX
Peers
Sector
Relationship
P/E Ratio
−24.4x−1.5x−0.5x
PEG Ratio
2.270.030.00
Price/Book
3.1x2.2x2.6x
Price / LTM Sales
-11.9x2.9x
Upside (Analyst Target)
313.5%236.3%66.3%
Fair Value Upside
Unlock14.1%10.2%Unlock

Analyst Ratings

16 Buy
2 Hold
0 Sell
Ratings:
18 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 95.444
(+298.68% Upside)

Earnings

Latest Release
Feb 05, 2025
EPS / Forecast
-0.32 / -0.28
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Viking Therapeutics Inc (VKTX) Stock Price Today?

The Viking Therapeutics Inc stock price today is 23.94.

What Stock Exchange Does Viking Therapeutics Inc Trade On?

Viking Therapeutics Inc is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Viking Therapeutics Inc?

The stock symbol for Viking Therapeutics Inc is "VKTX."

What Is the Viking Therapeutics Inc Market Cap?

As of today, Viking Therapeutics Inc market cap is 2.69B.

What is Viking Therapeutics Inc Earnings Per Share?

The Viking Therapeutics Inc EPS is -1.01.

What Is the Next Viking Therapeutics Inc Earnings Date?

Viking Therapeutics Inc will release its next earnings report on 22 Apr 2025.

From a Technical Analysis Perspective, Is VKTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.